Journal Article

Co-trimoxazole versus azithromycin for the treatment of undifferentiated febrile illness in Nepal: study protocol for a randomized controlled trial

KC, Raj Kumar, Shrestha, Ritu, Karkey, Abhilasha, Wolbers, Marcel, Basnyat, Buddha, Arjyal, Amit, Phuong, Dung Nguyen Thi, Karki, Manan, Thapa, Rajkumar, Kestelyn, Evelyne, Thwaites, Guy, Poudyal, Buddhi, Dongol, Sabina, Bhuju, Abhusani, Mahat, Saruna Pathak, Pokharel, Sunil, Baker, Stephen

2017

Overview

Background Undifferentiated febrile illness (UFI) includes typhoid and typhus fevers and generally designates fever without any localizing signs. UFI is a great therapeutic challenge in countries like Nepal because of the lack of available point-of-care, rapid diagnostic tests. Often patients are empirically treated as presumed enteric fever. Due to the development of high-level resistance to traditionally used fluoroquinolones against enteric fever, azithromycin is now commonly used to treat enteric fever/UFI. The re-emergence of susceptibility of Salmonella typhi to co-trimoxazole makes it a promising oral treatment for UFIs in general. We present a protocol of a randomized controlled trial of azithromycin versus co-trimoxazole for the treatment of UFI. Methods/design This is a parallel-group, double-blind, 1:1, randomized controlled trial of co-trimoxazole versus azithromycin for the treatment of UFI in Nepal. Participants will be patients aged 2 to 65 years, presenting with fever without clear focus for at least 4 days, complying with other study criteria and willing to provide written informed consent. Patients will be randomized either to azithromycin 20 mg/kg/day (maximum 1000 mg/day) in a single daily dose and an identical placebo or co-trimoxazole 60 mg/kg/day (maximum 3000 mg/day) in two divided doses for 7 days. Patients will be followed up with twice-daily telephone calls for 7 days or for at least 48 h after they become afebrile, whichever is later; by home visits on days 2 and 4 of treatment; and by hospital visits on days 7, 14, 28 and 63. The endpoints will be fever clearance time, treatment failure, time to treatment failure, and adverse events. The estimated sample size is 330. The primary analysis population will be all the randomized population and subanalysis will be repeated on patients with blood culture-confirmed enteric fever and culture-negative patients. Discussion Both azithromycin and co-trimoxazole are available in Nepal and are extensively used in the treatment of UFI. Therefore, it is important to know the better orally administered antimicrobial to treat enteric fever and other UFIs especially against the background of fluoroquinolone-resistant enteric fever. Trial registration ClinicalTrials.gov, ID: NCT02773407 . Registered on 5 May 2016.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Analysis / Antibiotics / Antimicrobial agents / Azithromycin / Biomedicine / Care and treatment / Clinical trials / Co-trimoxazole / Comparative analysis / Deoxyribonucleic acid / Dihydrofolate reductase / DNA / Dosage and administration / Drug dosages / Drug therapy / Enteric fever / Epidemiology / Fever / Fever clearance time / Health Sciences / Illnesses / Infections / Medicine / Medicine & Public Health / Patients / Salmonella / Statistics for Life Sciences / Study Protocol / Trimethoprim-sulfamethoxazole (Drug combination) / Tropical diseases / Typhoid fever / Typhus / Undifferentiated febrile illness / Viral infections